Otamixaban clinical trials
How each study uses otamixaban is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2010 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Factor Xa inhibitors source
Studies
Open first, then newest update. How each study uses otamixaban is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive StrategyCompletedPhase 3SanofiNCT01076764Written as Otamixaban
- Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary SyndromeCompletedPhase 2SanofiNCT00317395Written as Otamixaban (XRP0673)
- Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal ImpairmentCompletedPhase 1SanofiNCT01120314Written as OTAMIXABAN (XRP0673)
- Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic ImpairmentCompletedPhase 1SanofiNCT01126086Written as otamixaban XRP0673
- The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary InterventionCompletedPhase 2SanofiNCT00133731Written as Otamixaban (XRP0673)
Codes
What other systems call otamixaban · ClinicalTrials.gg INT004378
- MeSH (NLM) C435830otamixabanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S173RED00LOTAMIXABANConfirmed FDA, NLM, Wikidata
- Wikidata Q7108427otamixabanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90704OtamixabanOne source FDA
- DrugBank DB06635One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C435830 | otamixaban | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S173RED00L | OTAMIXABAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7108427 | otamixaban | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90704 | Otamixaban | One source FDA |
| DrugBank | DB06635 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.